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Abstract: Wheat bran (WB) is a constituent of whole grain products with beneficial effects for human
health. Within the human colon, such insoluble particles may be colonized by specific microbial
teams which can stimulate cross-feeding, leading to a more efficient carbohydrate fermentation
and an increased butyrate production. We investigated the extent to which WB fractions with
different properties affect the fermentation of other carbohydrates in the colon. Ten healthy subjects
performed four test days, during which they consumed a standard breakfast supplemented with 10 g
13C-inulin. A total of 20 g of a WB fraction (unmodified WB, wheat bran with a reduced particle size
(WB RPS), or de-starched pericarp-enriched wheat bran (PE WB)) was also added to the breakfast,
except for one test day, which served as a control. Blood samples were collected at regular time
points for 14 h, in order to measure 13C-labeled short-chain fatty acid (SCFA; acetate, propionate
and butyrate) concentrations. Fermentation of 13C-inulin resulted in increased plasma SCFA for
about 8 h, suggesting that a sustained increase in plasma SCFA can be achieved by administering
a moderate dose of carbohydrates, three times per day. However, the addition of a single dose of
a WB fraction did not further increase the 13C-SCFA concentrations in plasma, nor did it stimulate
cross-feeding (Wilcoxon signed ranks test).
Keywords: colonic fermentation; short-chain fatty acids; wheat bran; inulin
1. Introduction
The short-chain fatty acids (SCFA) acetate, propionate, and butyrate, constitute a major class of
bacterial metabolites that are derived from colonic carbohydrate fermentation. They are increasingly
considered as signaling molecules with a beneficial impact on gut and systemic health [1,2]. Indeed,
besides serving as energy substrates for the colonocytes, SCFA influence the expression of many genes
by acting as inhibitors of histone deacetylases, and affect metabolic processes through the activation of
G-protein coupled receptors (GPR41 and GPR43, later renamed as free fatty acid receptor (FFAR)-3
and (FFAR)-2). Several studies have indicated that SCFA, and in particular butyrate, improve the
intestinal barrier function and reduce inflammation by inhibiting NFκB activation [3,4]. In addition,
SCFA that enter the systemic circulation modulate energy homeostasis, and peripheral glucose and
lipid metabolism [4–6]. Furthermore, SCFA regulate immune function by affecting T cell differentiation
into effector and regulatory T cells (Treg) [7], and colonic Treg cell homeostasis [8].
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As a consequence, strategies that target the microbiota to improve health often aim at increasing
saccharolytic fermentation. The production of colonic SCFA may be stimulated by modulating the
intestinal microbiota and increasing the numbers of acetate and butyrate producing bacteria via
administration of probiotics. Many probiotics are selected strains of lactobacilli or bifidobacteria [9],
which are known lactate and acetate producers. In addition, there is a growing interest in the use
of butyrate producing bacteria, such as Faecalibacterium prausnitzii and Butyrcicoccus pullicaecorum,
as probiotics [10–13].
An alternative strategy for increasing SCFA production is to stimulate the indigenous saccharolytic
bacterial population by administration of prebiotics or fermentable dietary fibers [14]. The best studied
prebiotic substrates are inulin-type fructans (comprising oligofructose), galacto-oligosaccharides,
xylo-oligosaccharides, and arabinoxylanoligosaccharides. In vitro fermentation studies with fecal
inocula indicate that the amount and proportion of SCFA produced, depends on the type of fermentable
substrate [15]. For example, inulin-type fructans induce a relatively high proportion of acetate, whereas
resistant starch favors butyrate production [16].
Here, we applied a third strategy for modulating the entire intestinal ecosystem, which involves
the administration of disperse insoluble particles that act as platforms on which the bacteria can
adhere, grow, and interact. We hypothesize that these particles facilitate the exchange of microbial
nutrients and metabolites, resulting in a more complete carbohydrate fermentation and increased
cross-feeding. For example, the production of butyrate requires collaboration between primary
degraders, such as bifidobacteria, that produce acetate and lactate, and butyrate producing bacteria,
such as Faecalibacterium and Roseburia, that convert acetate into butyrate [17,18]. This interaction may
be facilitated if both species adhere to the dietary platforms. Wheat bran (WB) was selected as an
interesting dietary component for this purpose, as bacterial communities attached to WB that was
incubated in vitro with human fecal inocula, were found to be dominated by Clostridium cluster XIVa
bacteria, known as butyrate producers [19]. In addition, WB can be easily technically modified to
control its physical properties. In this study, we evaluated the impact of three WB fractions that differed
in particle size and tissue composition, on the fermentation of a readily fermentable carbohydrate
(13C-inulin) in healthy subjects. Concentrations of 13C-SCFA were measured in plasma as an indication
of carbohydrate fermentation and the relative proportions of acetate, propionate, and butyrate, were
considered as a marker of cross-feeding.
2. Materials and Methods
2.1. WB Fractions
2.1.1. Unmodified WB
Commercial WB with a particle size of 1690 µm was obtained from Dossche Mills (Deinze,
Belgium) and was used without further modification. Its chemical composition (amounts of dietary
fiber, starch, protein, lipid, and ash) was analysed as previously described [20–22].
2.1.2. Wheat Bran with Reduced Particle Size (WB RPS)
The unmodified commercial WB mentioned above was milled in a Cyclotec 1093 Sample mill
(FOSS, Höganäs, Sweden), as described previously [22], in order to obtain WB particles with an average
size of 150 µm.
2.1.3. Destarched Pericarp-Enriched Wheat Bran (PE WB)
PE WB was ascertained from Fugeia N.V. (Leuven, Belgium) and was obtained after an amylase
and xylanase treatment of untreated WB, as described by Swennen et al. [23]. Subsequently,
the PE WB was reduced in particle size to about 280 µm, using the same method as mentioned above.
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2.2. Fermentable Substrate
Highly 13C-enriched inulin with an atom percent (AP) beyond 97% was purchased from Isolife
(Wageningen, The Netherlands) and was mixed with unlabeled native inulin (Fibruline instant,
Cosucra Groupe Warcoing SA, Warcoing, Belgium; AP 0.98%), to form a homogeneous mixture
with an AP of 1.93%.
2.3. Study Population
Ten healthy men and woman, aged between 18 and 65 years, were recruited to participate in the
study. All subjects had a body mass index (BMI) between 18 and 27 kg/m2 and a regular diet defined
as three meals per day, on at least five days per week. Exclusion criteria were the use of antibiotics,
prebiotics and probiotics, in the month preceding the study and during the study, consumption of
a low calorie diet or another special diet in the month prior to the study, the use of medication that
could affect the gastrointestinal tract in the two weeks before the start of the study and during the
study, abdominal surgery in the past (except for appendectomy), chronic gastrointestinal diseases,
blood donation in the three months prior to the study, hemoglobin (Hb) levels below reference values,
and for woman, pregnancy or breast feeding. Subjects that had participated in a clinical trial involving
radiation exposure in the year prior to the study were also excluded. The study protocol conformed to
the Declaration of Helsinki and was approved by the Ethics Committee of the University of Leuven
(Belgian Registration Number: B322201423101). All participants signed written informed consent.
The study has been registered at ClinicalTrials.gov (clinical trial number: NCT02422537).
2.4. Study Design
Each subject performed four test days, with at least one week in between each test. During
the three days prior to each test day, subjects were instructed to consume a low fiber diet,
consisting of a maximum of one piece of fruit per day, white bread instead of wholegrain products,
and no more than 100 g vegetables per day. They were also asked to avoid alcohol consumption.
On the evening prior to the test day, the subjects consumed a completely digestible and non-fermentable
meal (lasagna), eventually supplemented with white bread. After an overnight fast, the subjects
presented themselves at the laboratory and provided two basal breath samples for the measurement
of 13CO2 and 14CO2. A catheter (BD, Erembodegem, Belgium) was placed into an antecubital vein
in the forearm to collect all blood samples during the test day. After collection of a basal blood
sample, a standard breakfast was administered to the subjects. The breakfast consisted of 250 g low-fat
yoghurt labeled with inulin-14C-carboxylic acid (74 kBq, Perkin Elmer, Boston, MA, USA), a marker
for oro-cecal transit time (OCTT), and 10 g of 13C-labeled inulin, which served as a model fermentable
substrate. The OCTT was defined as the time that elapses between the intake of the meal, and the
arrival in the colon, which is reflected by the appearance of 14CO2 in the breath. Depending on the
test day, the breakfast was further supplemented with 20 g of one of the three WB fractions, or no
supplement on the control test day. The participants were blind to the order of the different WB
fractions and control tests, which were randomized using online software [24]. Breath samples were
collected every 20 min, up to 14 h after consumption of the breakfast. Blood samples were collected
every hour during the first 4 h, every 40 min from 4 h to 10 h, and again every hour from 10 h to 14 h.
A light digestible meal was offered to the subjects 4 h and 8 h after consumption of the breakfast. Water
was offered ad libitum during the whole test day. The course of a test day is represented in Figure 1.
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Figure 1. After a standard breakfast, labeled with 13C-inulin, inulin-14C-carboxylic acid and a WB
fraction, breath samples were collected for the measurement of 13CO2 and 14CO2 and blood samples
were collected for the analysis of 13C-SCFA concentrations for 14 h. A light standardized meal was
administered after 4 h and 8 h. The participants were blind to the order of the different WB fractions
and control tests, which were randomized.
2.5. Collection and Analysis of Breath Samples
Subjects deposited breath samples for the analysis of 13CO2 by blowing through a straw, into a
12-mL glass tube (Exetainer®, Labco Ltd., Ceredigion, UK), whereas samples for the measurement of
14CO2 were collected by blowing through a pipet, int a plastic scintillation vial (Sar tedt, Nümbrecht,
Germany) contai ing 4 mL of a 0.5 M hyamine hydroxide solution (Perkin El er, Boston MA, USA).
Thymolp taleine acted as a color indic tor, which became disc lored when 2 mol CO2 was exhaled.
The abundance of 13CO2 was measured using isotope ratio mass spectrometry (ABCA, Sercon,
Crewe, UK) and the results were expressed as delta over baseline (DOB). 14CO2 was measured using
β-scintillation counting (Packard Tricarb Liquid Scintillation Spectrometer, model 3375, Packard
Instruments, Downers Grove, IL, USA), after addition of 10 mL hionic fluor (Perkin Elmer, Boston
MA, USA), and was expressed as disintegrations per minute (DPM) [25]. The arrival time of the
breakfast in the colon (OCTT) and the start of the fermentation, were defined as the time at which a
significant increase in 14CO2 and 13CO2, respectively, from the background was observed in the breath.
This increase was defined as 2.5 times the standard deviation of all previous points, above the running
average of all previous points [26].
2.6. Analysis of Plasma 13C-Abundance
Blood samples were centrifuged at 3000× g and 4 ◦C for 10 min to obtain plasma. The samples
were immediately aliquoted and stored at −80 ◦C until analysis. Plasma samples were deproteinized
using A icon® Ultra-15 filters (Molecular eight cut-off: 0 kDa, Merck, Kenilw rth, NJ, USA).
Before application of the sample, the filters were rinsed twice using 0.2 N HCl to avoid SCFA
contamination. Subsequen ly, 3 mL plasma as mixed with 3 mL MilliQ® water (Sarto ius Arium®
611-VF, Sartorius, Göttingen, Germany) and 150 µL 0.15 N NaOH, and centrifuged at 2000× g and
4 ◦C for 20 min. Following this, the samples were transferred to the cleaned filters and deproteinized
by centrifugation at 3000× g and 4 ◦C for 3 h. After addition of 120 µL 1 M NaOH, the filtrate was
dried overnight in a vacuum concentrator (RVC 2-18, Christ, Germany) at 50 ◦C.
Prior to injection, the dried samples were acidified with 100 µL 4 M HCl with trypan blue
(0.4%, Sigma, UK), and extracted in 400 µL diethyl ether (Sigma-Aldrich, Steinheim, Germany).
The ether layer was pipetted into a crimp neck vial (1.5 mL) and evaporated with nitrogen gas
(N2) to about 50 µL, before injection in the gas chromatograph combustion isotope ratio mass
spectrometer (GC-C-IRMS) (Delta plus-XP, Thermo Fisher, Bremen, Germany), equipped with a
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trace gas chromatograph (Interscience, Breda, The Netherlands) and a combustion interface type 3
(Thermo Fisher). Four µL of the SCFA solution was injected on an AT-Aquawax-DA column
(30 m × 0.53 mm, i.d., 1.00 µm, Grace, Lokeren, Belgium), with the injector temperature at 240 ◦C.
Helium 5.0 was used as a carrier gas at a constant flow of 2.5 mL/min. The initial oven temperature
was held at 80 ◦C for 3 min and was increased by 4 ◦C/min to 140 ◦C, then further increased by
8 ◦C/min to 240 ◦C, and kept at this temperature for 10 min. The separated GC-effluents were
combusted and oxidised to NOx, CO2, and H2O in an oxidation furnace (CuO/NiO/Pt) at 940 ◦C [25].
All oxidised components were passed over the reduction column at 640 ◦C and the H2O in the system
was eliminated by a Nafion membrane (Thermo Fisher). The delta (δ13 Pee Dee Belemnite (PDB))
values were calculated by Isodat 2.0 software (Thermo Fisher) and converted to AP. The measured
AP at any time point t was subtracted from the abundance measured in the baseline sample at time
point 0, to obtain results in atom per cent excess (APE) [25]. The linearity of the system (slope < 0.06)
was confirmed to be in the range between 0.8 and 11 volts, with CO2 as the reference gas (5.0 quality,
δ = −32.16‰).
2.7. Analysis of Total SCFA Concentrations in Plasma
The total concentration of acetate, propionate, and butyrate in the plasma was measured using
gas chromatography coupled with a flame ionization detector (GC-FID) after preconcentration of
the SCFA, using a hollow fiber liquid membrane extraction. Plasma samples were thawed prior to
analysis, and prepared and analyzed as described by Zhao et al. [27], with slight modifications. Plasma
samples (100 µL) were rapidly spiked with internal standard (12.5 µg 2-ethyl butyric acid and 30 µg
3-methyl-valeric acid), acidified with 20 µL 0.2 N HCl, and diluted to 1.5 mL. A hollow fiber coated
with tri-n-octylphoshphine oxide and filled with 10 µL 0.15 N NaOH, was immersed in the diluted
plasma and shaken overnight. In this way, protonated SCFA diffuse into the fiber, where they become
ionized and remain trapped. After acidification of the fiber content, 0.5 µL of the acidified SCFA
solution was injected in a GC (HP 6890 series, Agilent, Wilmington, NC, USA) equipped with a FID
and a DB-FAPP capillary column (30 m × 0.53 mm id, 1.00 µm film, Agilent, Wilmington, NC, USA).
Helium was used as a carrier gas at a flow rate of 4.2 mL/min. The initial oven temperature was
100 ◦C for 3 min, raised by 4 ◦C/min to 140 ◦C, and held at this temperature for 5 min, before being
further increased by 40 ◦C/min to 235 ◦C, and finally held at 235 ◦C for 5 min. The temperature of
the FID heater and the injection port were set at 240 ◦C and 200 ◦C, respectively. The flow rates of
hydrogen, air, and nitrogen as the make-up gas, were 30, 300, and 20 mL/min, respectively.
2.8. Calculations
At each time point, the concentration of 13C-SCFA in plasma is the sum of the concentration that















[13C-SCFA]t0 is the concentration of 13C-SCFA present in plasma at time point 0 and[13C-SCFA]colon is the concentration of 13C-SCFA coming from the colon at time point t.
Substitution of the concentration of 13C-SCFA by the product of its total concentration and
abundance, results in Equation (2).
nt × APt = n0 × APplasmat0 + ncolon × APcolon (2)
In addition, the total concentration of SCFA at each time point t is the sum of the SCFA already
present in the plasma, and the SCFA produced in the colon (Equation (3)).
nt = n0 + ncolon (3)
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Substitution of n0 by nt-ncolon in Equation (2), allows one to calculate the concentration of
SCFA originating from the colon, thus produced from the 13C-inulin at a time point t, according to
Equation (4).







where ncolon is the concentration of SCFA originating from the colon; nt is the total concentration
of SCFA at time point t; APt is the AP of 13C-acetate, 13C-propionate, or 13C-butyrate at time
point t; APcolon is the AP of the administered inulin; APplasmat0
is the atom percent of 13C-acetate,
13C-propionate, or 13C-butyrate in the plasma at time point t0.
The concentrations of 13C-acetate, 13C-propionate, and 13C-butyrate, originating from the colon at
each time point, were used to draw concentration versus time curves for each test day. Subsequently,
the cumulative concentrations of 13C-acetate, 13C-propionate, and 13C-butyrate (area under the curve
(AUC)) were calculated using the trapezoidal rule and were expressed in µmol·h/L.
The starting point of the fermentation was ascertained by calculating the mean time at which
13C-acetate, 13C-propionate, and 13C-butyrate concentrations in plasma increased. The end of the
fermentation was the mean time at which 13C-acetate, 13C-propionate, and 13C-butyrate concentrations
returned to the baseline. The duration of the fermentation was the difference between the end and
start points of the fermentation.
2.9. Statistical Analysis
Statistical analysis was performed using SPSS software, version 23.0 (IBM, Brussels, Belgium).
Because of the small sample size, non-parametric tests were used (Wilcoxon signed ranks test).
3. Results
3.1. Characterisation of the WB Fractions
Untreated WB had an average particle size of 1690 µm and was composed of 50% dietary fiber
(arabinoxylan, cellulose, β-glucan, lignin and fructan), 17% starch, 20% protein, 6% lipids, and 7%
ash (Figure 2a). WB RPS did not differ in tissue composition from the unmodified WB (Figure 2a).
In contrast, PE WB was composed of 71% dietary fiber (mainly insoluble), 2% starch, 18% protein,
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Figure 2. Unmodified wheat bran  (WB) and wheat bran with  reduced particle  size  (WB RPS)  (a) 
contain less total dietary fiber and more starch compared to destarched pericarp‐enriched wheat bran 
(PE WB) (b).   
Figure 2. Unmodified wheat bran (WB) and wheat bran with reduced particle size (WB RPS)
(a) contain less total dietary fiber and more starch compared to destarched pericarp-enriched wheat
bran (PE WB) (b).
3.2. Study Population
From the 58 subjects that responded to the advertisement, 15 subjects underwent screening,
which included an assessment of height and body weight, plasma Hb levels, medical history,
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and dietary habits (Figure 3). Five volunteers withdrew from the study before the start because
of a lack of time (n = 3), pregnancy (n = 1), or because they did not meet the inclusion criteria (n = 1).
Ten subjects (4M/6F, aged 25 ± 4 years, BMI 23.7 ± 2.0 kg/m2) completed the four test days according
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Figure 3. Flow chart depicting the passage of subjects through the study.
3.3. Estimation of the OCTT and the Start of the Fermentation Using Breath and Plasma Samples
The start of the fermentation was defined as the time point at which 13CO2 started to increase in
the breath, or as the ean time point at which the concentration of 13C-acetate, 13C-propionate, and
13C-butyrate started to increase in the plasma. An increase in breath 14CO2, which w s generated
from bacterial fermentation of 14C-labeled inulin carboxylic acid, was used as a marker for the OCTT.
Figure 4a,b compare the OCTT to the start of fermentation, based on breath 13CO2 excretion and
plasma 13C-SCFA concentrations, respectively. The increase in breath 13CO2 and in plasma 13C-SCFA
occurred slightly before the increase in breath 14CO2, suggesting that fermentation of 13C-inulin had
already started in the terminal ileum.Nutrients 2017, 9, 83  8 of 14 
 
 
Figure 4. Both  13C‐excretion  in breath (a) and plasma 13C‐SCFA concentrations (b) start to  increase 
before the increase in breath 14CO2 (n = 40). 
On average, the fermentation started 208.5 ± 29 min and 219 ± 24.2 min after consumption of the 
breakfast,  based  on  the  breath  samples  and  the  plasma  samples,  respectively.  The  start  of  the 











WB, WB RPS,  and PE WB were  administered  to  the  subjects,  compared  to  the  control  condition 
(Wilcoxon signed rank test; pWB = 0.201, p WBRPS = 0.236, pPEWB = 0.878) (Figure 6). 
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On average, the fermentation started 208.5 ± 29 min and 219 ± 24.2 min after consumption of
the breakfast, based on the breath samples and the plasma samples, respectively. The start of the
fermentation was not affected by the addition of any of the WB fractions, when compared to the
control (Wilcoxon signed ranks test; Breath samples: pWB = 0.073, pWBRPS = 0.125, pPEWB = 0.619;




Figure 4. Both  13C‐excretion  in breath (a) and plasma 13C‐SCFA concentrations (b) start to  increase 
before the increase in breath 14CO2 (n = 40). 
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Figure 5. Wheat bran (WB) sup lementati i t ffect the start of the fermentation based on the
13CO2-breath excretion ( 13C-lab led short-chain fatty acids (SCFA) concentrations in plasma
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3.4. Estimation of the Duration of the Fermentation in the Presence of Different WB Fractions
The duration of the fermentation was considered as a measure for the efficiency of fermentation
with shorter duration, indicating a more efficient fermentation. On average, fermentation continued
for 486 ± 40.9 min. However, the duration of the fermentation was not different when unmodified
WB, WB RPS, and PE WB were administered to the subjects, compared to the control condition


















Figure 7. Average plasma concentrations of  13C‐acetate  (a),  13C‐propionate  (b) and  13C‐butyrate (c) 
originating from the colon as a function of time (n = 40). 
Figure 6. Wheat bran (WB) su l t ti id not modify the duration of th fermentation (n = 10).
The middle line represents the mean it r deviation (whiskers).
3.5. 13C-SCFA Concentrations in Plasma Produced from the 13C-Labeled Inulin
Average concentrations of plasma 13C-acetate, 13C-propionate, and 13C-butyrate originating from
the colon, were presented as a function of time (Figure 7).
Influx of 13C-acetate, 13C-propionate, and 13C-butyrate from the colon, reached a maximum
value 360 ± 119 min after consuming the breakfast. Mean cumulative 13C-SCFA concentrations
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(n = 40) amounted to 18.5 ± 3.88 µmol·h·L−1 for acetate, 0.59 ± 0.17 µmol·h·L−1 for propionate,
and 0.99 ± 0.3 µmol·h·L−1 for butyrate. However, cumulative 13C-SCFA plasma concentrations
were not different in the presence of any WB fraction, when compared to the control condition
(Wilcoxon signed ranks test; Acetate: pWB = 0.114, pWBRPS = 0.878, pPEWB = 0.721; Propionate:
pWB = 0.169, pWBRPS = 0.646, pPEWB = 0.139; Butyrate: pWB = 0.169, pWBRPS = 0.721, pPEWB = 0.646;
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Figure 8. Wheat bran (WB) sup lement ti did not affect the cumulative 13C-acetate (a),
13C-propionate (b), 13C-butyrate (c), total 13C-SCFA (d) concentrations in plasma (n = 10). The middle
line represents the mean with the standard deviation (whiskers).
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3.6. Relative Proportion of Acetate, Propionate, and Butyrate after WB Supplementation
Stimulation of cross-feeding between colonic bacteria was evaluated by calculating the relative
proportion of acetate, propionate, and butyrate for the different conditions. However, none of the
WB fractions significantly influenced the relative proportion of acetate, propionate, and butyrate
in the plasma, when compared to the control (Wilcoxon signed rank test; Acetate: pWB = 0.721,
pWBRPS = 0.959, pPEWB = 0.575; Propionate: pWB = 0.959, pWBRPS = 0.445, pPEWB = 0.959; Butyrate:

















Figure 9. The proportions of 13C-acetate, 13 - r ionate, and 13C-butyrate in plasma were not aff cted
by wheat bran (WB) (n = 10).
4. Discussion
Colonic production of SCFA from undigested carbohydrates has been increasingly recognized as a
key process that contributes to both local gut and systemic health. The extent to which colonic-derived
SCFA reach the systemic circulation may be an important parameter that determines the systemic
health effects induced by dietary fiber consumption [25]. In the present study, we demonstrated
that plasma SCFA are temporarily increased after consumption of a moderate dose of an easily
fermentable carbohydrate.
The fact that we used uniformly stable isotope labeled inulin which, upon fermentation, resulted
in the formation of labeled SCFA, allowed us to selectively quantify in plasma those SCFA originating
from the inulin fermentation in the colon and to exclude confounders, like SCFA that were present in
the colon at the start of the test days, SCFA that might have been produced due to partial fermentation
of the WB fractions, or SCFA that have been endogenously produced. For example, plasma acetate is
also produced from fatty acid oxidation and amino acid metabolism [28], and during ketogenesis in
the mitochondria of the hepatocytes [29]. Colonic fermentation of 13C-inulin contributed to increased
plasma 13C-SCFA concentrations for about 8 h, with maximal concentrations 6 h after consumption
of the carbohydrate. It needs to be mentioned that the peak SCFA concentrations depend on the
transit time of the substrates through the gastrointestinal tract, which is, apart from host factors,
determined by the composition and caloric load of the breakfast meal and may vary with another
test meal. Nevertheless, the results suggest that sustained increased plasma levels of SCFA might be
obtained by three administrations of a considerable dose of an easily fermentable carbohydrate, evenly
spread over a 24-h period. Furthermore, experiments which evaluate the health benefits of fermentable
carbohydrates or prebiotics that are attributed to systemic SCFA, should preferably be performed in a
time window between 6 and 10 h after administration of the carbohydrate.
To investigate whether insoluble particles could stimulate the fermentation of other carbohydrates
in the colon, we used WB fractions that differed in tissue composition and particle size. Although
reduction of particle size does not alter the composition of the WB fraction, it clearly modifies the
physical properties of the WB. Destruction of cell walls during milling increases the specific surface area
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and the accessibility of intracellular cell components to degrading enzymes and, in this way, augments
the fermentability of the WB fractions. In contrast, PE WB has been stripped of any fermentable material
and mainly contains highly cross-linked dietary fiber that is hardly fermentable. We hypothesized that
PE WB might facilitate fermentation by providing a platform on which bacteria can adhere, resulting
in a more efficient exchange of microbial nutrients and metabolites between different types of bacteria;
so-called cross-feeding. RPS WB may act in the same way, but has the additional advantage of being
partly fermentable. If we would compare PE WB with a dinner table to which the bacteria draw up,
WB RPS would be a dinner table filled with nutrients. Hence, we expected WB RPS to be more efficient
in stimulating carbohydrate fermentation and cross-feeding.
Several factors may explain why WB did not stimulate the fermentation of inulin. First, inulin is
an easily and rapidly fermentable substrate for colonic bacteria. It is possible that the fermentation
proceeds so efficiently in baseline conditions that no room is left for improvement by the additional
administration of WB platforms. Future studies may be performed with less rapidly fermentable
carbohydrates, such as arabinoxylanoligosaccharides (AXOS). These oligosaccharides consist of a
xylose backbone that is substituted with arabinose residues. By varying the degree of polymerization
(DP) and the degree of substitution (DS), the rate of fermentation can be modulated. Unfortunately,
13C-labeled AXOS derivatives are not commercially available. Second, the appearance of 13CO2 in the
breath and of 13C-SCFA in the plasma, consistently occurred before arrival of the test meal in the colon,
indicated by the appearance of 14CO2 in the breath, suggesting that the fermentation of inulin had
already started in the terminal ileum, where the bacterial density rapidly increases [30]. We used native
inulin, which is a mixture of oligo- and polysaccharides, with a DP varying from 3 to 70 and an average
DP of 25. The presence of short fructo-oligosaccharides most likely explains the early fermentation,
as fermentation of short oligosaccharides proceeds more easily than that of longer chains [31]. Indeed,
studies that use the increase in breath hydrogen excretion after administration of inulin as a marker
of OCTT [26,32,33], generally use Raftiline HP® (Beneo, Mannheim, Germany) as the substrate,
which only contains the long chains of inulin. This, at least in part, physical disconnection between the
site of fermentation (terminal ileum) and main location of bacteria (colon), might hamper stimulation
of the carbohydrate fermentation by bacteria adhered to the WB fractions.
Finally, repeated administration, rather than a single dose of WB, might have been more efficient
for inducing a more efficient bacterial ecosystem. Nevertheless, in vitro incubation of human fecal
samples with insoluble WB, showed that within 24 h (no earlier time point was tested) WB was
already colonized by subsets of bacteria, suggesting a rapid colonization of insoluble particles [19].
Few studies have evaluated the impact of insoluble particles on SCFA production in vivo.
Administration of resistant starch (RS) to pigs for two weeks resulted in increased cecal concentrations
of butyrate, whereas combined administration of RS and WB resulted in increased butyrate
concentrations in the more distal parts of the colon and in feces, suggesting that the addition of
WB distally shifted fermentation [34]. These results could not be explained by partial fermentation
of WB, as WB alone did not significantly increase butyrate concentrations. Also in humans, a diet
supplemented with WB and RS for three weeks resulted in higher fecal proportions of butyrate and
lower propionate proportions than WB alone, whereas fecal SCFA concentrations after the WB diet
were not different from the values recorded during the control diet [35]. These observations support our
hypothesis of improved carbohydrate fermentation due to the colonization of WB particles. However,
alternative mechanisms also need to be considered. Increased fecal SCFA may also be due to the fact
that WB accelerates whole gut transit time [36]. Indeed, both in vitro fermentation studies and human
studies, indicate that SCFA production is increased with short transit time, and that longer transit
times are associated with a shift from carbohydrate to protein fermentation [37–39]. It is important to
note that fecal SCFA concentrations are the net result of production and absorption, and are difficult to
relate to plasma SCFA.
Finally, we observed large inter- and intra-individual variations in plasma SCFA concentrations,
which may have hampered detection of subtle changes in plasma SCFA due to WB intervention.
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Such large variations have also been reported in previous studies measuring SCFA [40–42] and may
be due to variability in intestinal microbiota composition, colonic SCFA absorption and metabolism,
and SCFA metabolism in the liver.
5. Conclusions
In this study, we showed that fermentation of a readily fermentable substrate results in increased
plasma SCFA for about 8 h, suggesting that a sustained increase in plasma SCFA concentrations can
be achieved when a moderate dose of fermentable carbohydrate is administered three times per day.
Nevertheless, the addition of a single dose of different WB fractions did not further increase either the
fermentation of the readily fermentable inulin, or cross-feeding between gut bacteria.
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